Research & Literature

Immune-mediated Liver Injury in Hepatitis B Virus Infection.

Oh IS, Park SH

Immune network 2015; (15(4)):191-8 doi:10.4110/in.2015.15.4.191.

[Treatment of chronic hepatitis B virus infection and hepatocellular carcinoma prevention].

Soudan D, Sultanik P, Pol S

Presse medicale (Paris, France : 1983) 2015; (44(12 Pt 1)):1251-5.

Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.

Liang KH, Hsu CW, Chang ML, et al.

The Journal of infectious diseases 2016; (213(6)):966-74 doi:10.1093/infdis/jiv547.

[Analysis of the hepatitis B report data on pilot surveillance in 200 counties in China, 2013].

Miao N, Zhang G, Zheng H, et al.

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2015; (49(9)):766-70.

Stiffness Value and Serum Biomarkers in Liver Fibrosis Staging: Study in Large Surgical Specimens in Patients with Chronic Hepatitis B.

Lu Q, Lu C, Li J, et al.

Radiology 2016; (280(1)):290-9 doi:10.1148/radiol.2016151229.

Review article: novel therapies for hepatitis B virus cure - advances and perspectives.

Lin CL, Kao JH

Alimentary pharmacology & therapeutics 2016; (44(3)):213-22 doi:10.1111/apt.13694.

Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.

Tsai MC, Chen CH, Hu TH, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2017; (116(7)):512-521 doi:10.1016/j.jfma.2016.08.006.

The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors.

Li ZQ, Hu CL, Yu P, et al.

Clinics and research in hepatology and gastroenterology 2017; (41(3)):311-318 doi:10.1016/j.clinre.2016.11.007.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of hepatology 2017; (67(2)):370-398 doi:10.1016/j.jhep.2017.03.021.

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Terrault NA, Lok ASF, McMahon BJ, et al.

Hepatology (Baltimore, Md.) 2018; (67(4)):1560-1599 doi:10.1002/hep.29800.

Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Tzartzeva K, Obi J, Rich NE, et al.

Gastroenterology 2018; (154(6)):1706-1718.e1 doi:10.1053/j.gastro.2018.01.064.

Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection.

Tseng TC, Liu CJ, Su TH, et al.

Alimentary pharmacology & therapeutics 2018; (47(11)):1480-1489 doi:10.1111/apt.14619.

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.

Yoo J, Hann HW, Coben R, et al.

Diseases (Basel, Switzerland) 2018; (6(2)) doi:10.3390/diseases6020027.

Chronic Hepatitis B Infection: A Review.

Tang LSY, Covert E, Wilson E, Kottilil S

JAMA 2018; (319(17)):1802-1813 doi:10.1001/jama.2018.3795.

Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.

Ko C, Chakraborty A, Chou WM, et al.

Journal of hepatology 2018; (69(6)):1231-1241 doi:10.1016/j.jhep.2018.08.012.

Unmet need in chronic hepatitis B management.

Liang LY, Wong GL

Clinical and molecular hepatology 2019; (25(2)):172-180 doi:10.3350/cmh.2018.0106.

Countdown to 2030: eliminating hepatitis B disease, China.

Liu J, Liang W, Jing W, Liu M

Bulletin of the World Health Organization 2019; (97(3)):230-238 doi:10.2471/BLT.18.219469.

External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.

Lee HW, Kim SU, Park JY, et al.

Liver international : official journal of the International Association for the Study of the Liver 2019; (39(9)):1624-1630 doi:10.1111/liv.14129.

Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.

Yang Y, Zhao X, Wang Z, et al.

Hepatology (Baltimore, Md.) 2020; (71(4)):1154-1169 doi:10.1002/hep.30897.

[Effect of antiviral therapy on the occurrence of hepatitis B-related hepatocellular carcinoma].

Sun J, Zhang S, Wang YX, et al.

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2019; (27(9)):721-724 doi:10.3760/cma.j.issn.1007-3418.2019.09.014.

[Natural History and Treatment Indications of Chronic Hepatitis B].

Sinn DH

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2019; (74(5)):245-250 doi:10.4166/kjg.2019.74.5.245.

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.

Kaneko S, Kurosaki M, Joko K, et al.

Scientific reports 2020; (10(1)):13021 doi:10.1038/s41598-020-69522-w.

A perspective of the relationship of serum HBV DNA and HBsAg apportioned by the same hepatic parenchyma cell volume with inflammation in the natural history of chronic hepatitis B.

Tan L, Wu ZQ, Zhao C, et al.

Annals of palliative medicine 2021; (10(2)):1388-1395 doi:10.21037/apm-20-635.

Serum Biomarkers for the Prediction of Hepatocellular Carcinoma.

Debes JD, Romagnoli PA, Prieto J, et al.

Cancers 2021; (13(7)) doi:10.3390/cancers13071681.

Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.

Li B, Liu Z, Liu X, et al.

Hepatology international 2021; (15(5)):1103-1108 doi:10.1007/s12072-021-10235-1.

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B.

Sprinzl MF, Feist C, Koch S, et al.

BMC health services research 2021; (21(1)):846 doi:10.1186/s12913-021-06794-6.

HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage.

Wang Y, Li Y, Zai W, et al.

Hepatology (Baltimore, Md.) 2022; (75(5)):1275-1288 doi:10.1002/hep.32245.

[Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021; (29(10)):932-941 doi:10.3760/cma.j.cn501113-20210927-00484.

Consensus on the secondary prevention of primary liver cancer.

Nan Y, Xu X, Gao Y, et al.

Hepatology international 2021; (15(6)):1289-1300 doi:10.1007/s12072-021-10259-7.

Assessment of liver fibrosis by transient elastography and multi-parameters model in young children with chronic hepatitis B virus infection.

Luo H, Peng S, Ouyang W, et al.

BMC infectious diseases 2022; (22(1)):160 doi:10.1186/s12879-022-07142-7.

Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.

Kayes T, Crane H, Symonds A, et al.

Alimentary pharmacology & therapeutics 2022; (56(3)):510-518 doi:10.1111/apt.17040.

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History.

Bonino F, Colombatto P, Brunetto MR

Viruses 2022; (14(8)) doi:10.3390/v14081691.

Increasing prevalence of chronic hepatitis B virus infection and low linkage to care in Denmark on 31 December 2016 - an update based on nationwide registers.

Bollerup S, Wessman M, Hansen JF, et al.

Infectious diseases (London, England) 2023; (55(1)):17-26 doi:10.1080/23744235.2022.2125065.

Hepatitis B functional cure and immune response.

Zheng JR, Wang ZL, Feng B

Frontiers in immunology 2022; (13()):1075916 doi:10.3389/fimmu.2022.1075916.

A computational study of a stochastic fractal-fractional hepatitis B virus infection incorporating delayed immune reactions via the exponential decay.

Qurashi MA, Rashid S, Jarad F

Mathematical biosciences and engineering : MBE 2022; (19(12)):12950-12980 doi:10.3934/mbe.2022605.

Therapeutic targets in alcohol-associated liver disease: progress and challenges.

Adekunle AD, Adejumo A, Singal AK

Therapeutic advances in gastroenterology 2023; (16()):17562848231170946 doi:10.1177/17562848231170946.

What Is the Current Status of Hepatitis B Virus Viro-Immunology?

Boni C, Rossi M, Montali I, et al.

Clinics in liver disease 2023; (27(4)):819-836 doi:10.1016/j.cld.2023.05.001.

Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation.

Campbell C, Wang T, Gillespie I, et al.

Public health 2024; (226()):215-227 doi:10.1016/j.puhe.2023.10.036.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.

Nam H, Han JW, Lee SK, et al.

Journal of gastroenterology and hepatology 2024; (39(8)):1673-1683 doi:10.1111/jgh.16593.

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B.

Gopalakrishna H, Ghany MG

Current hepatology reports 2024; (23(2)):241-252 doi:10.1007/s11901-024-00652-9.

[Strategic considerations in health economics for the complete treatment of patients with chronic HBV infection].

Zhang SH, Cui FQ

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2024; (32(5)):406-410 doi:10.3760/cma.j.cn501113-20240414-00204.

Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.

Janssen HLA, Lim YS, Lampertico P, et al.

The lancet. Gastroenterology & hepatology 2024; (9(8)):718-733 doi:10.1016/S2468-1253(24)00096-7.

Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis.

Zhang L, Wu HD, Qian YF, Xu HY

World journal of clinical cases 2024; (12(25)):5749-5760 doi:10.12998/wjcc.v12.i25.5749.

Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.

Buti M, Lim YS, Chan HLY, et al.

Alimentary pharmacology & therapeutics 2024; (60(11-12)):1573-1586 doi:10.1111/apt.18278.

A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B.

Wang H, Wu L

Pakistan journal of medical sciences 2024; (40(10)):2390-2394 doi:10.12669/pjms.40.10.10307.

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

Hwang SY, Danpanichkul P, Agopian V, et al.

Clinical and molecular hepatology 2025; (31(Suppl)):S228-S254 doi:10.3350/cmh.2024.0824.

Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase.

Chen S, Huang L, Chu Y, et al.

Scientific reports 2025; (15(1)):3031 doi:10.1038/s41598-025-87756-4.

Detection of hepatitis B virus surface antigen, IgM and IgG antibodies to hepatitis B virus core antigen in the clinical classification and epidemiological surveillance of HBV infection.

de Almeida Pondé RA

Molecular biology reports 2025; (52(1)):195 doi:10.1007/s11033-025-10278-9.

Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do.

Abdelhamed W, El-Kassas M

Liver research 2024; (8(2)):83-90 doi:10.1016/j.livres.2024.05.004.

Accelerators of chronic hepatitis B fibrosis cirrhosis CCND1 gene expression and promoter hypomethylation.

Chen N, Luo P, Tang Y, et al.

Scientific reports 2025; (15(1)):10630 doi:10.1038/s41598-025-93778-9.

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of hepatology 2025; (83(2)):502-583 doi:10.1016/j.jhep.2025.03.018.

Identifying Adherence Trajectories in Chronic Hepatitis B: A Cluster-Based Approach to Long-Term Treatment Management.

Zhang L, Ji H, Pang S, et al.

Journal of viral hepatitis 2025; (32(10)):e70068 doi:10.1111/jvh.70068.

The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virus-related cirrhosis.

Kilic G, Guvenir T, Bodakci E, et al.

Hepatology forum 2025; (6(4)):141-145 doi:10.14744/hf.2024.2024.0069.

Shifts in Cohort Eligibility With Deimplementation of Race-specific Guidance for Hepatocellular Carcinoma Surveillance.

Macedo B, McDonald J, Dash A, et al.

Gastro hep advances 2026; (5(1)):100773 doi:10.1016/j.gastha.2025.100773.

The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B.

Han J, Xu L, Li Y, et al.

Frontiers in immunology 2025; (16()):1708909 doi:10.3389/fimmu.2025.1708909.

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB.

Kang SH, Yim HJ, Han SK, et al.

Journal of gastroenterology and hepatology 2026; (41(5)):1583-1589 doi:10.1111/jgh.70326.

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

You H, Maiwall R, Chen J, et al.

Hepatology international 2026; doi:10.1007/s12072-026-11108-1.

[APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].

You H, Maiwall R, Chen J, et al.

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2026; (34(7)):640-667 doi:10.3760/cma.j.cn501113-20260416-00155.